<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>NDRG2 (N-Myc downstream-regulated gene 2) is aberrantly expressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and related to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation status </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we investigated the association between NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> to determine whether levels of NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> could predict relapse and survival </plain></SENT>
<SENT sid="2" pm="."><plain>A hospital-based study cohort of 226 CRC patients was involved in the study </plain></SENT>
<SENT sid="3" pm="."><plain>NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were determined by real-time PCR </plain></SENT>
<SENT sid="4" pm="."><plain>Correlations of NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> clinicopathologic features, disease-free survival, and overall survival of the patients were studied </plain></SENT>
<SENT sid="5" pm="."><plain>Significant decreased expression of NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> was detected in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens </plain></SENT>
<SENT sid="6" pm="."><plain>NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression significantly correlated with differentiation status (P &lt; 0.001), lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P &lt; 0.001), and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> stage (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with reduced level of NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> had a statistically significantly shorter disease-free survival and overall survival duration than patients with preserved expression of NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis, NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> level was found to be an independent prognostic factor for both disease-free survival and overall survival of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="9" pm="."><plain>The present research provided the first evidence that decreased NDRG2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in primary human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> might be a powerful, independent predictor of recurrence and outcome </plain></SENT>
</text></document>